Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Down 8.4% – Should You Sell?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) fell 8.4% on Wednesday . The stock traded as low as $0.32 and last traded at $0.33. 80,811,016 shares traded hands during trading, an increase of 160% from the average session volume of 31,034,150 shares. The stock had previously closed at $0.36.

Analyst Ratings Changes

Separately, StockNews.com assumed coverage on shares of Tonix Pharmaceuticals in a report on Wednesday. They issued a “hold” rating on the stock.

Tonix Pharmaceuticals Stock Down 4.8 %

The firm has a fifty day moving average price of $0.24 and a 200 day moving average price of $0.37. The firm has a market capitalization of $58.68 million, a price-to-earnings ratio of -0.01 and a beta of 2.23. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.81 and a current ratio of 3.33.

Tonix Pharmaceuticals (NASDAQ:TNXP) last posted its earnings results on Tuesday, November 12th. The company reported ($0.23) EPS for the quarter, topping analysts’ consensus estimates of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. The company had revenue of $2.82 million for the quarter, compared to the consensus estimate of $2.63 million. As a group, sell-side analysts expect that Tonix Pharmaceuticals Holding Corp. will post -17.63 EPS for the current fiscal year.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.